Annona senegalensis extract demonstrates anticancer properties in N-diethylnitrosamine-induced hepatocellular carcinoma in male Wistar rats by Yakubu, Omolara Faith et al.
Biomedicine & Pharmacotherapy 131 (2020) 110786
Available online 30 September 2020
0753-3322/© 2020 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Original article 
Annona senegalensis extract demonstrates anticancer properties in 
N-diethylnitrosamine-induced hepatocellular carcinoma in male Wistar rats 
Omolara F. Yakubu a,*, Damilohun S. Metibemu b, Isaacson B. Adelani a, Gbolahan O. Adesina a, 
Chidera B. Edokwe a, Oyinkansola E. Oseha a, Abiodun H. Adebayo a,* 
a Department of Biochemistry, College of Science and Technology, Covenant University, Canaan Land, Ota PMB 1023, Ogun State, Nigeria 
b Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Ondo State, Nigeria   






A B S T R A C T   
Background: Hepatocellular carcinoma (HCC) is a common and leading cancer around the globe. This study 
investigated the anticancer properties of extract of Annona senegalensis in N-diethylnitrosamine (DEN) - induced 
hepatocellular carcinoma in male Wistar rats. 
Methods: Rats were simultaneously induced with a combination of 100 mg/kg b.wt of DEN and 0.5 mL/kg of 
carbon tetrachloride (CCl4) intraperitoneally once a week for three weeks in a row. Thereafter, animals were 
treated with 100 mg/kg and 200 mg/kg b.wt of A. senegalensis extract daily for 21days. Analysis using gas 
chromatography-mass spectrometry (GC–MS) was carried out to discover the phytoconstituents contained in the 
n-hexane extract of A. senegelensis. The levels of liver function parameters and antioxidant enzyme activities were 
determined via spectrophotometric analysis. Reverse transcriptase-polymerase chain reaction technique was 
used to assess the gene expression patterns of BCL-2, P53, P21, IL-6, FNTA, VEGF, HIF, AFP, XIAP, and EGFR 
mRNAs. 
Results: Treatment of DEN-induced hepatocellular carcinoma Wistar rats with the extract caused significant 
(p < 0.05) decrease in the activities of ALT and AST. It also resulted in a reduction of the concentration of MDA 
and a significant increase (p < 0.05) in SOD and GSH activities. IL-6, BCL-2, VEGF, EGFR, XIAP, FNTA, and P21 
mRNAs expressions were significantly (p < 0.05) downregulated after treatment. Histopathological analysis 
revealed that the extract improved the liver architecture. 
Conclusion: A. senegelensis n-hexane extract demonstrates its anticancer properties by improving the liver ar-
chitecture, increasing the antioxidant defense systems, downregulating the pro-inflammatory, anti-apoptotic, 
angiogenic, alpha-fetoprotein and farnesyl transferase mRNAs expression and hitherto up-regulate the expression 
of tumor suppressor (P21 and P53) mRNAs.   
1. Introduction 
Nitrosamines are formed by combining nitrates or nitrites with 
amines. Diethylnitrosamine (DEN) is a type of nitrosamines, which is a 
known hepatocarcinogen forming DNA adducts in the liver [1]. Induc-
tion of oxidative stress by DEN further contributes to the pathogenesis of 
hepatocellular carcinoma [2,3]. DEN and other known hepatocarci-
nogens induce hepatic injury by enhancing the proliferation of cells, 
which is accompanied by hepatocellular necrosis [4,5]. They target the 
liver where they are bio-transformed via the cytochrome 
p450-dependent mechanism, CYP2E1, explicitly resulting in DNA- ad-
ducts [6,7]. Hepatic carcinogenesis is ranked the fifth most prevalent 
cancer and usually influenced by agents such as alcohol, phenobarbital, 
2-acetylaminofuorene, and DEN [8]. Animal models are viewed as a 
critical tool for studying hepatic carcinogenesis and are often used for 
cancer research. Studies have reported early induction of oxidative 
stress, inflammation, and proliferation by DEN in rat models [9,10]. 
Medicinal plants and herbs contain phytochemicals and natural 
sources of antioxidants. The significance of these active metabolites has 
prompted important scientific interest in their biological activities. 
Annona senegalensis (AS) is one such plant containing an abundance of 
phytochemicals; it contains alkaloids, flavonoids, glycosides, tannins, 
saponins, steroids, and anthocyanins [11–13]. AS is often referred to as 
wild soursop; the plant is a 2− 5 m tall shrub having blue to greenish, 
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oblong, alternate, and simple leaves. It is prominent among the Northern 
region of Nigeria and commonly called in Hausa language, Gwándàn 
dààjìì [14,15]. Almost all the plant parts have been reported useful for 
medicinal applications. The leaves are used for yellow fever, tubercu-
losis, and smallpox treatment while the stem bark is employed for 
treating hernia and snakebite [16,17]. The root is employed to ease 
swallowing, impotence, and an antidote for poison; root bark helps in 
the treatment of infectious diseases while the juice from the plant dries 
up chickenpox on the skin [18–20]. Several studies have documented its 
biological activities such anticonvulsant [21–24], antimicrobial [25], 
antiplasmodial [26], anti venomous [27,28], spermatogenic [29], 
anti-inflammatory, analgesic [30,31] and antihelmintic activities [32, 
33]. This study aimed to ascertain the anticancer effect of Annona sen-
egalensis leaf extract on hepatocellular carcinoma induced by dieth-
ylnitrosamine in Wistar rats. 
2. Materials and methods 
2.1. Collection and identification of plants 
A. senegalensis leaf samples were collected around Ile-Ife in Osun 
State, Nigeria. A botanist, Dr. J.O. Popoola from Biological Science 
Department, Covenant University, Nigeria, identified the leaf. Samples 
were deposited in the Herbarium at the Forest Research Institute of 
Nigeria (FRIN) with voucher no 112597. 
2.1.1. Processing of plant samples 
The leaves were processed using methods by Younoussa et al. [34]. 
Fresh leaves of A. senegalensis was dried with ambient air at 25 ◦C for 
eight weeks, after which an electric blender was used to pulverize it. The 
powdered leaves (4.5 kg) were further soaked for 72 h in N-hexane, 
filtered using a filter paper (Whatman No. 2) and concentrated using a 
rotary evaporator at 40 ◦C to give a final weight of 161.8 g of the extract 
and percentage yield of 3.6. 
2.2. Gas chromatography–mass spectrometry analysis 
This was carried out with the aid of Agilent Technologies (6890 
Series) GC connected to (5973 Series) Selective Mass Detector. The 
carrier gas (helium) with the oven temperature set at 50 ◦C (for 2 min) 
and raised steadily at 4 ◦C/minute; after which 2.0 μL of the diluted 
sample was introduced at a ratio of 1–50 (1:50). The GC model series 
6890 was linked to the NIST/NBS 20 database for comparing the com-
pounds’ mass spectra to authentic samples. 
2.3. Chemicals 
N-Diethylnitrosamine (DEN) and carbon tetrachloride (CCl4) were 
purchased from AK Scientific USA and local vendors, respectively. The 
test kits were procured through local vendors from Randox Laboratories. 
All other chemicals used were of analytical grades. 
2.4. Animals 
Thirty-six healthy six-week-old male rats (150 g) were obtained from 
the Animal Holding unit of Lagos State University Teaching Hospital, 
Nigeria. They were housed in clean plastic cages with adequate venti-
lation conditions (12/12 h light/dark cycle) and given food and water ad 
libitum, acclimatized for two weeks. The rats were maintained following 
the National Institute of Health guidelines on handling laboratory ani-
mals [35]. Ethical approval was obtained from the Research Ethical 
Committee of Covenant University, Ota, Nigeria, and was assigned an 
approval no NHREC/25/10/2018. 
2.5. Study design 
The rats (36) were grouped into six groups. Three groups (B to D) 
were induced intraperitoneally (IP) with 100 mg/kg of DEN and 0.5 mL/ 
kg b.wt of carbon tetrachloride (CCl4) weekly for the first three weeks 
while groups A, E, and F took corn oil (the vehicle). Treatment of groups 
C and D started by the 4th week with 100 and 200 mg/kg of the extract 
respectively for three weeks; 100 and 200 mg/kg body weight of extract 
were administered to groups E and F respectively while group A received 
the vehicle all through the experiment [36]. 
A (Control): Standard diet and corn oil 
B (Negative control): Intraperitoneal administration with 100 mg/kg 
of DEN and 0.5 mL/kg b.wt of carbon tetrachloride (Toxicant) 
C: Toxicant +100 mg/kg b.wt of A. senegalensis 
D: Toxicant +200 mg/kg b.wt of A. senegalensis 
E: 100 mg/kg b.wt A. senegalensis only 
F: 200 mg/kg b.wt A. senegalensis only 
At the end of the treatment, the rats were fasted overnight and 
sacrificed the next morning via cervical dislocation. Samples were 
collected for biochemical assays, and the liver was excised, weighed, and 
a portion was fixed in 10 % formalin while the remaining were frozen at 
− 80 ◦C until needed for further analysis. 
2.6. Biochemical assays 
Biochemical parameters assayed using Randox commercial test kits 
include the following; alanine and aspartate aminotransferases (ALT and 
AST) [37,38], alkaline phosphatase (ALP) [39], and lactate dehydro-
genase (LDH) [40] were determined using Randox test kits and 
following the manufacturer’s instruction. Thiobarbituric acid reactive 
substances (TBARS) was measured to ascertain the microsomal lipid 
peroxidation levels [41]. Other antioxidant parameters include: reduced 
glutathione (GSH), superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) were analyzed following standard procedures 
[42–44]. 
2.7. RNA isolation and reverse transcription polymerase chain reaction 
TRIzol reagent (Gibco) was used for RNA isolation from the liver 
tissues; RNA-free DNase (Roche, Switzerland) was added to the isolated 
RNA and left at 37 ◦C for fifteen minutes while the RNeasy kit (Qiagen, 
Germany) was used for RNA purification. 40 μg of the RNA was allowed 
to incubate with the reverse transcriptase (GE Healthcare, UK) for an 
hour together with hexanucleotides for the synthesis of cDNA, adhering 
to the manufacturer’s instructions. This was followed by PCR amplifi-
cation using specific primers (Table 1) for 50 cycles using a thermal 
cycler (BioRad, USA). The amplicon bands were analyzed on 1% agarose 
Table 1 
List of target genes and specific primer sequences  
TARGET 
GENE 
FORWARD 5′-3’ REVERSE 5′-3’ 
FNTA GTGATCGCGCTGTGTTGGAG CGCACTCTCATTGTGTGGC 
IL 6 GACTTCCAGCCAGTTGCCTT GCAGTGGCTGTCAACAACAT 
P21 GAGAACTGGGGAGGGCTTTC TCCTGAGCCTGTTTCGTGTC 
VEGF CGGGCCTCTGAAACCATGAA GCTTTCTGCTCCCCTTCTGT 
HIF GCAACTGCCACCACTGATGA GCTGTCCGACTGTGAGTACC 
AFP CACCATCGAGCTCGGCTATT TCCCAAAAACTCGCTTGGGT 
P53 CCCCTGAAGACTGGATAACTGT TCTCCTGACTCAGAGGGAGC 
XIAP TGCATAATGAGGACTGGGGG GCCCCGATCAGGAAAAACAC 
EGFR GATTAATCCCGGAGAGCCAGA TGAGCCTGTTACTTGTGCCT 
BCL-2 GGTGAACTGGGGGAGGATTG AGAGCGATGTTGTCCACCAG 
β-actin CCCGCAGACTTGGAGAAAGT GTTTCGATGGCCTTCATCGC 
*FNTA: Farnesyltransferase, IL-6: Interleukin-6, VEGR: Vascular endothelial 
growth factor, HIF: Hypoxia-inducible factors, AFP: Alpha-fetoprotein, XIAP: X- 
linked inhibitor of apoptosis protein, EGFR: Epidermal growth factor receptor, 
BCL-2: B-cell lymphoma-2. 
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and stained with ethidium bromide [45]. 
2.8. Histopathology 
Liver tissues fixed in formalin (10 %) were sliced into to 2.1 mm 
thick; dehydrated with ethanol, handled with paraffin wax, and then 
cast into blocks; sections of the tissue were diced into 5 μm and left to 
dry on a slide. Haematoxylin-eosin stain was used to stain the blocks and 
then analyzed using a light microscope [46,47]. 
2.9. Statistical analysis 
GraphPad (6.0) was used for the statistical analysis, while group 
comparisons were done using one-way ANOVA. All values were reported 
as mean ± SEM (standard error of the mean) using a 95 % confidence 
interval. 
3. Results 
3.1. GCMS analysis 
The analysis revealed 60 bioactive compounds (Fig. 1 and Table S1). 
The compound identified having the lowest retention time of 4.56 min 
was Dimethyl Sulfoxide, while the Oleoyl chloride had a retention time 
of 19.98 min. It is believed that different phytoconstituents are respon-
sible for the biological activities of the crude extract [48]. Fig. 1 and 
Table S1 show the chromatogram and the phytoconstituents of 
A. senegalensis n-hexane extract, respectively. 
3.2. Effects of A. senegalensis extract on N-diethylnitrosamine-induced 
hepatocellular carcinoma in male wistar rats on selected liver enzymes 
The impact of A. senegalensis on serum ALT, AST, ALP, and liver 
homogenate LDH activities is presented in Fig. 2. Significant (p < 0.05) 
increase in the activities of ALT, AST, ALP, and LDH in group 2 (negative 
Fig. 1. Chromatogram of A. senegalensis extract.  
Fig. 2. Effect of A. senegalensis extract on liver function parameters in albino Wistar rats. Values are reported as mean ± SEM of 6 replicates; *p < 0.05 is considered 
significant as compared to negative control; #p < 0.05 is considered significant as compared to normal control. (a) ALT: Alanine aminotransferase; (b) AST: Aspartate 
aminotransferase; (c) ALP: Alkaline phosphatase; (d) LDH: Lactate dehydrogenase. 
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control) was observed while upon treatment with the extract 
(A. senegalensis), the enzymes’ activities were observed to be signifi-
cantly reduced. Group D (Induced group treated with 200 mg/kg of 
extract) was found to be more effective in reducing the activities of the 
enzymes. 
3.3. Effect of A. senegalensis extract on N-diethylnitrosamine-induced 
hepatocellular carcinoma in male Wistar Rats on hepatic antioxidant 
status 
Induction of the animals with DEN without treatment (negative 
control) resulted in significant (p < 0.05) increase in malondialdehyde 
(MDA) concentration as compared to the control group (group A). 
A. senegalensis lowered the elevated MDA concentration in a dose- 
dependent manner as seen in Fig. 3. GSH level significantly (p < 0.05) 
reduced in the DEN-induced untreated group (negative control) in 
comparison to the normal control group. Subsequent treatment with the 
extract produced a notable rise in the GSH level. SOD and GPx as in-
dicators of antioxidant status were also measured in the liver tissue 
homogenate. Significant depletion (p < 0.05) in their activities was 
observed in the untreated group as against the normal control (A) while 
both activities were significantly (p < 0.05) elevated in both treated 
Fig. 3. Effect of A. senegalensis extract on antioxidant parameters in albino Wistar rats. (a) MDA: malondialdehyde; (b) GSH: reduced glutathione; (c) SOD: su-
peroxide dismutase; (d) GPx: glutathione peroxidase. Values were reported as mean ± SEM of 6 replicates. *p < 0.05 is considered significant as compared to negative 
control; #p < 0.05 is considered significant as compared to normal control. 
Fig. 4. Relative expression of IL-6 mRNA in the liver of N-Diethylnitrosamine induced-hepatocellular carcinoma rats following treatment with A. senegalensis extract. 
Bars with different alphabet depict significant differences. Bars with the same alphabet show no significant difference. P < 0.05 is statistically significant. 
Fig. 5. Relative expressions of (A) BCL-2 and (B) XIAP mRNAs in the liver of N-Diethylnitrosamine induced-hepatocellular carcinoma rats following treatment with 
A. senegalensis extract. Bars with different alphabet depict significant differences. Bars with the same alphabet show no significant difference. p < 0.05 is considered to 
be statistically significant. 
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groups (C and D) as compared with the untreated group (B). 
3.4. mRNAs Profiling of the effects of A. senegalensis extract in N- 
diethylnitrosamine induced-hepatocellular carcinoma in Wistar rats 
3.4.1. Expression of inflammatory mRNA, Interleukin-6 (IL-6) 
As revealed in Fig. 4, IL-6 mRNA was significantly up-regulated in 
the negative control (B) when compared with group A (normal control). 
IL-6 expression was significantly reduced by treatment with the different 
doses used (groups C and D). There is no significant expression of IL-6 
mRNA in group E when compared with group A. However, the expres-
sion of IL-6 mRNA was significantly downregulated in group F when 
compared with A. 
3.4.2. Expression of anti-apoptotic mRNAs, X-linked inhibitor of apoptosis 
protein (XIAP), and B-cell lymphoma 2 (BCL-2) 
In Fig. 5a, the expression of XIAP mRNA was significantly down-
regulated by the treatments, groups C and D, when compared with group 
B. XIAP gene expression, was downregulated in group F when compared 
with A and B. Also, in Fig. 5b BCL-2 gene expression was significantly 
up-regulated in group B when compared to A. However, it was signifi-
cantly down-regulated by the treatments in groups C and D on 
comparing with group B. There was a significant downregulation in the 
expression of BCL-2 gene in group F as compared with both groups A and 
C. 
3.4.3. Expression of angiogenic mRNAs, Epidermal growth factor receptor 
(EGFR), vascular endothelial growth factor (VEGF) and Hypoxia-Inducible 
Factor (HIF)-1 
In Fig. 6, expressions of EGFR, HIF-1, and VEGFR mRNAs were up- 
regulated significantly (p < 0.05) in group B when compared with 
group A. On the other hand, the expressions of EGFR, HIF-1, and VEGFR 
mRNAs were significantly downregulated by the treatments (C and D) as 
compared with the untreated group (B). 
3.4.4. Expression of cell-cycle mRNAs, p21, and p53 
The p21 mRNA was significantly up-regulated in group B as 
compared with group A (Fig. 7a). Significant downregulation of the p21 
mRNA in group C was observed when compared with group B. However, 
200 mg/kg b.wt of the extract (group D) up-regulated the expression of 
p21 mRNA when compared with the negative control (B). A dose- 
dependent downregulation of p21 mRNA in groups E and F was 
observed when compared to group B. Fig. 7b shows the expression of 
p53 mRNA was significantly downregulated in the negative control 
Fig. 6. Relative expressions of (A) EGFR, (B) HIF-1, and (C) VEGFR mRNAs in the liver of N-Diethylnitrosamine induced-hepatocellular carcinoma rats following 
treatment with A. senegalensis extract. Bars with different alphabet depict significant differences. Bars with the same alphabet show no significant difference. P < 0.05 
is statistically significant. 
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when compared with the control group. p53 mRNA expression was 
however, significantly up-regulated in group C when compared with 
group B. No significant difference in the expression of p53 mRNA in 
group D was observed upon comparing with group B, while its expres-
sion was significantly up-regulated in group E. 
3.4.5. Expression of Farnesyltransferase (FNTA) mRNA 
In Fig. 8, the expression of FNTA mRNA was significantly up- 
regulated in the negative control group (B) as against group A. Its 
expression was significantly downregulated in groups C, D, E, and F 
when compared with groups A and B. 
3.4.6. Expression of Alpha-fetoprotein (AFP) mRNA 
In Fig. 9, the expression of AFP mRNA was up-regulated in group B. 
Meanwhile, the expression of AFP mRNA was significantly down-
regulated in groups D and E as compared with both control groups (A 
and B). However, there was no significant expression of AFP mRNA in 
groups C and F when compared with group A. The expression of AFP 
Fig. 7. Relative expressions of p21 and p53 mRNAs in the liver of N-Diethylnitrosamine induced-hepatocellular carcinoma rats following treatment with 
A. senegalensis extract. Bars with different alphabet depict significant differences. Bars with the same alphabet show no significant difference. P < 0.05 is considered 
to be statistically significant. 
Fig. 8. Relative expressions of FNTA mRNA in the liver of N-Diethylnitrosamine induced-hepatocellular carcinoma rats following treatment with A. senegalensis 
extract. Bars with different alphabet depict significant differences. Bars with the same alphabet show no significant difference. p < 0.05 is significant. 
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mRNA in groups C, D, E, and F were significantly downregulated when 
compared with group B. 
4. Discussion 
A total of sixty (60) phytochemicals were identified from the n- 
hexane crude extract (see Table S1). Oleoyl chloride (9.7 %) constitute 
the highest percentage of phytoconstituents. The antimicrobial and 
endotoxin-neutralizing effects of Oleoyl compounds have been reported 
[49]. Also present in the N-hexane crude extract are; 912-Octadecadie-
noic acid (Z,Z)-, 2-hydroxy (7.89 %), performic acid (4.89 %), erythritol 
(4.47 %), 912-Octadecadienoic acid (Z,Z)- (4.30 %), 9-Octadecenoic 
Fig. 9. Relative expressions of AFP mRNA in the liver of N-Diethylnitrosamine induced-hepatocellular carcinoma rats following treatment with A. senegalensis 
extract. Bars with different alphabet depict significant differences. Bars with the same alphabet show no significant difference. p < 0.05 is significant. 
Fig. 10. Photomicrograph of liver tissues (H 
and E, x400) of rats A) with normal liver 
morphology in the control group, B) induced 
with the toxicant, C) treated with 100 mg/kg, 
D) treated with 200 mg/kg, E) administered 
100 mg/kg, F) administered 200 mg/kg body 
weight of A. senegalensis extract. A) liver section 
of rat of the normal control showing normal 
liver morphology (blue arrow); the central ve-
nules appear normal (white arrows), the sinu-
soids appear normal (slender black arrow) 
without infiltration of inflammatory cells B) 
liver section showing cytoplasmic fat infiltra-
tion (blue arrow) and necrotic hepatocyte (red 
arrow). C) liver section showing normal venules 
(white arrow), sinusoids appear normal 
(slender arrow) with the absence of inflamma-
tory cell infiltrations D) liver section with 
normal central venules (white arrow), the si-
nusoids show the focal area of mild inflamma-
tory cells aggregate (slender arrow) with 
normal hepatocytes features (blue arrow) E) 
liver section showing normal central venules, 
sinusoids (white and thin arrows) F) liver sec-
tion showing normal hepatocyte morphology 
and normal central venules (blue and white 
arrows respectively) (For interpretation of the 
references to colour in this figure legend, the 
reader is referred to the web version of this 
article).   
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acid (Z)-, 2-hydroxy-1-(hyd (4.16 %), 9-Octadecenoic acid (Z)-, methyl 
ester (3.62 %) (Table S1). The anticancer potentials of 9, 12-Octadeca-
dienoic acid (Z, Z)-, 2-hydroxy, performic acid, and 912-Octadecadie-
noic acid are have all documented [50–52]. 
Diethylnitrosamines are acute carcinogens and hepatotoxins. It has 
been documented to arbitrate deleterious effects in tissues via induction 
of oxidative stress [53]. In our study, the anticancer potential of 
A. senegalensis (AS) leaf extract on DEN-induced hepatocellular carci-
noma in rats was investigated. DEN caused a significant (p < 0.05) in-
crease in serum AST, ALT, ALP, and LDH levels when compared with the 
control group (Fig. 2). A rise in serum levels of these enzymes has been 
linked to detrimental liver architecture integrity as they leak into the 
bloodstream due to cellular damage [54]. Treatment with A. senegalensis 
decreased the enzyme levels significantly (p < 0.05) when compared to 
DEN-induced untreated group, which suggests that AS could effectively 
impede DEN-induced liver cell damage. These results corroborate with 
the histological findings where the hepatocytes of the DEN-induced 
untreated group showed traces of cytoplasmic fat infiltration (blue 
arrow) and degeneration; and necrotic hepatocytes were also seen (red 
arrow; Fig. 10b) while the groups treated with AS showed liver section 
with normal venules (white arrow; Fig. 10c) with normal hepatocytes 
and liver morphology (blue arrow; Fig. 10d). However, group F 
(200 mg/kg b.wt of extract only) showed a significant increase in ALT, 
AST and LDH when compared with normal control (grp A), but there is 
no correlation between the biochemical result and histology results as 
the histology shows the liver tissues in group E and F with normal he-
patocyte morphology and normal central venules. 
Studies have shown that cancerous cells shift from aerobic to an 
anaerobic mechanism where glucose is converted to lactate. Since LDH 
catalyzes the conversion of pyruvate to lactate, it, therefore, contributes 
to tumor progression by renewing NAD+ supply for the glycolytic 
pathway, reducing pH for tumor invasion and thus activating immune 
response [55]. Langhammer et al. [56] and Brown et al. [57] described 
the expression of LDH in colon and breast tissue cancer. Lactate dehy-
drogenase A (LDHA), an isoform of LDH was found to be up-regulated in 
clinical samples of human hepatocellular carcinoma (HCC) [58]. Hence, 
this corroborates with the result observed in this study where LDH levels 
were significantly (p < 0.05) elevated in DEN-induced untreated group 
(B), which could be needed for the tumor progression. AS significantly 
(p < 0.05) reduced LDH levels in the treated groups, which suggests that 
LDH could be a promising target for averting and treatment of cancer 
(Fig. 2d); as LDH has been reported to be a key player and potential 
target in cancer therapy [59]. 
Oxidative stress entails the disparity between production and 
buildup of reactive oxygen species (ROS) in tissues and/or cells. When 
an imbalance occurs, there is an elevation of ROS production, and then 
lipid peroxidation prevails [60]. Increased MDA indicates the escalation 
of lipid peroxidation since it is a peculiar biomarker of oxidative stress 
[61]. Significant elevation of MDA levels observed in the untreated 
DEN-induced group (B), which could be a result of the overproduction of 
ROS and inadequate antioxidant defense; however, AS significantly 
reduced the MDA levels in a dose-dependent manner (Fig. 3a). The result 
of this study is in line with other studies where elevated lipid peroxi-
dation was observed in tumors and malignant cells, including breast and 
liver tissues [62,63]. However, our findings were contradictory to that of 
Punnonen et al. [64] where they reported lower levels of 
thiobarbituric-acid reactive material in the cancerous tissue of breast 
cancer patients 
Superoxide dismutase (SOD) is a metalloenzyme that converts su-
peroxide radicals to hydrogen peroxides. With high oxidative meta-
bolism, it is spread out in the cells, protecting them from the harmful 
effect of superoxide anions [65]. In this study, decreased activity of SOD 
in DEN-induced untreated rats (grp B) was observed while the 
extract-treated groups showed significant (p < 0.05) increase nearing 
normal levels (Fig. 3c); this corresponds to previous studies where 
diminished activity of SOD has been linked to cancer cell progression 
[66,67]. Increased expression of SOD activity in the treated groups may 
be a way to recoup and protect the body from oxidative stress. 
In contrast, the decreased activity suggests a higher consumption of 
antioxidative enzymes. GSH and GPx also protect against damage by 
providing a first-line defense and eliminating the reactive intermediates 
via conjugation [68,69]. As shown in Fig. 3, there was a decrease in the 
liver GSH (Fig. 3b) and GPx (Fig, 3d) in group B. The treated groups (C 
and D), however, showed a significant (p < 0.05) rise in the GSH con-
centration only, although a minor (not notable) increase in GPx was also 
observed; suggesting the extract defense against free radicals. 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine that intervenes in 
infections, diseases, and cancer [70]. IL-6 in hepatocellular carcinoma 
(HCC) is documented to be a prognostic and distinct marker in cancer 
studies [71,72]. The up-regulation of IL-6 mRNA in group B (Fig. 4) 
corroborated the report of Li et al. [73] that the expression of IL-6 aids 
the progression of hepatocellular carcinoma. Hepatocellular 
carcinoma-inducing potential of DEN/CCl4 is hinged on 
pro-inflammation [74] hence the upregulation of IL-6 mRNA. The 
anti-inflammatory potentials demonstrated by A. senegalensis extract 
herein is in tandem with the report of Yeo et al. [30] that A. senegalensis 
possess anti-inflammatory potentials. Increased expressions of IL-6 in 
our study show HCC development can be explained with a simultaneous 
increase in the epidermal growth factor (EGF) gene expression in the 
negative control group. In a study designed to understand tumorigenic 
effects of EGFR signaling pathway in Kupfer cells, it was shown that DEN 
administration might have activated the expression of IL-6 which also 
link the high expression of IL-6 in HCC progression to increased 
expression of EGF as EGF deficiency failed to promote the expression of 
IL-6 [75]. This was also corroborated with the suggestion that Toll-like 
receptor and EGFR pathways are triggered during liver carcinogenesis, 
thus activating the expression of tumor necrosis factor (TNF) and 
interleukin-6 (IL-6) [76]. 
Apoptosis is an essential systematic process in which chronic liver 
damage can be regulated by BCL-2 proteins. While the pro-apoptotic 
genes instigate apoptosis, anti-apoptotic genes, including BCL-2, 
inhibit apoptosis [77]. X-linked Inhibitor-of-apoptosis Protein (XIAP) 
could play a crucial role in blocking the extrinsic and intrinsic pathways 
in apoptosis [78,79]. XIAP and BCL-2 are anti-apoptotic proteins and are 
overexpressed in malignancy [80]. The up-regulation of BCL-2 and XIAP 
mRNAs in group B (Fig. 5) demonstrated the resistance of malignant 
cells to apoptosis due to the co-administration of DEN and CCl4 which 
can be associated with increased gene copy number, transcription and 
translational processes of BCL-2 protein as seen in different 
cancer-related case [81,82]. It is worthy of note that treatments with the 
extract significantly downregulated the expressions of BCL-2 and XIAP 
mRNAs (Fig. 5) The proapoptotic tendencies demonstrated by 
A. senegalensis extract in the present study conforms with the earlier 
report by Adisa et al. [83] that A. senegalensis extract demonstrated 
apoptosis in HeLa cells. 
The inverse expression of vascular endothelial growth factor (VEGF) 
compared to that of p53 in negative control (B) reported in our study 
could also be attributed to VEGF role in angiogenetic pathway leading to 
HCC. VEGF has been suggested to enhance HCC through alteration in the 
PKCα/p53 pathway [84]. Activation of angiogenesis and reduced sur-
vival rate in the growth and progression of HCC has also been reported 
[85]. In addition, hypoxic conditions also resulted in increased VEGF 
protein concentration [86]. This hypoxia-induced VEGF increased 
expression has thus been described as an essential step in HCC related 
angiogenesis [87]. Thus, the increased VEGF expression observed in the 
DEN + CCl4 induced group (group B) could have been activated by an 
increased expression of HIF, which was also reported in the study 
(Fig. 6). Annona senegalensis extract demonstrated anti-angiogenic 
properties as observed in this study, EGFR, HIF-1, and VEGFR mRNAs 
were significantly downregulated in groups C and D in comparison with 
group B (Fig. 6). EGFR, HIF-1, and VEGF angiogenic related genes have 
all been implicated in pathogenesis and development of neoplasm [88]. 
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The anti-angiogenic potentials demonstrated herein by the Annona 
senegalensis extract is in tandem with the report of Yi et al. [89] that 
Annona atemoya, a family (Annonaceae) of the Annona demonstrates 
anti-angiogenic potentials. 
p21 induces cell cycle arrest, and it is overexpressed in the presence 
of oxidative stress [90,91]. The expression of p21 mRNA was signifi-
cantly up-regulated in the group administered DEN/CCl4 (group B) 
when compared with other groups (Fig. 7a); this may be due to oxidative 
stress associated with the toxicant (DEN/CCl4) [74]. It suffices to say 
that 100 mg/kg body weight of A. senegalensis (group C) significantly 
downregulated the expression of p21 mRNA; hence A. senegalensis 
extract demonstrates cell cycle arrest. The upregulation of the tumor 
suppressor p53 mRNA in group C as compared to group B depicts 
A. senegalensis might bring about its anticancer activities by 
up-regulating the p53 tumor suppressor mRNA (Fig. 7b). 
The tumor suppressor gene (p53) plays a crucial role in tumor sup-
pression through the regulation of the cell cycle. However, its protective 
role could be lost due to the co-administration of the carcinogens. This 
loss of function, which has been reported in various cancer studies, 
could be linked to “trans-dominant suppression” of the protein expres-
sion. Despite the ability of p53 to be oncogenic through mutation [92], 
the reverse was the case in our study. The “trans-dominant suppression” 
of p53, as reported, may have been a result of its interaction and for-
mation of a heteromer with a mutant form of p53, thus causing a com-
plete loss of function of the non-mutated p53 gene [93]. BCL-2 and p53 
genes were part of the earliest discoveries in cancer research, thus giving 
a possible relationship between the two. The regulation of BCL-2 by p53 
occurs through various mechanisms involving direct or indirect activa-
tion of BCL-2 genes. Despite different mechanisms involved, reduced 
expression of p53 coupled with an increased expression of BCL-2 could 
be linked to apoptosis regulation, where the low expression of p53 can 
be attributed as activation of liver tumorigenesis [94]. Despite a possible 
relationship between p53 and XIAP expression, as described by Li et al. 
[95], we observed differential expression between the two genes when 
compared to the normal group. The dual functional role of p53 
explained earlier as either oncogenic or has its expression suppressed 
[93]. We cannot, however, confirm a non-existent relationship between 
the two genes. Our extract at 100 mg/kg (group E) effectively increased 
the expression of p53 (Fig. 7b). 
Farnesyltransferases (FNTA) are post-translational modification 
proteins responsible for the oncogenic transformation of proteins. In-
hibition of farnesyltransferase is shown to demonstrate anticancer 
properties [96]. Blocking Ras activation through inhibition of farnesyl-
transferase has been shown to induce growth arrest in neoplastic cells 
[97]. Interestingly, treatments with A. senegalensis extract significantly 
downregulate FNTA mRNA expression in comparison with both controls 
(A and B). Furthermore, the expression of FNTA mRNA in groups E and F 
were equally downregulated by A. senegalensis extract when compared 
with groups A and B (Fig. 8). The present results showed that 
A. senegalensis possess inhibitory roles on farnesyltransferase. The re-
ported anticancer properties of A. senegalensis is likely due to its inhi-
bition of farnesyltransferase activity [83]. 
Alpha-fetoprotein (AFP) is an established biomarker of hepatocel-
lular carcinoma (HCC) [98]. The significant upregulation of AFP mRNA 
in group B is believed to be a result of tumor-induced by DEN and CCl4. 
The significant downregulation in the expression of AFP mRNA in all the 
treatment groups (C and D) and groups E and F by A. senegalensis extract 
further give credence to its anticancer potentials (Fig. 9) [83]. 
In conclusion, we demonstrated that the n-hexane extract of 
A. senegelensis has a protective ability against DEN-induced hepatocel-
lular carcinoma, and this protection is accomplished by counteracting 
the induction of oxidative stress by DEN via increasing the activity of 
SOD, GSH and GPx and down-regulation of specific genes. Further 
research can be tailored towards mechanism and possible drug devel-
opment from the extract of A. senegalensis. 
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